Clinical Trial: Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma

Clinical Trial: Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma

Sponsor and Collaborators

Duke University
Celgene Corporation

Contact
Contact: Donna Adams, ANP
(919) 668-4716
adams068@mc.duke.edu

Contact: Patricia Davis, RN
(919) 668-1026
davis043@mc.duke.edu

Principal Investigator
Anne W. Beaven, MD Duke University Medical Center Durham, NC USA

ClinicalTrials.gov Identifier

NCT01121757
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs